## 5/5/3

DIALOG(R) File 351: Derwent WPI

(c) 2004 Thomson Derwent. All rts. reserv.

## 007388666

WPI Acc No: 1988-022601/\*198804\*

XRAM Acc No: C88-009931

Pharmaceutical with stabilised granulocytes colony stimulating factor - contains surfactant, saccharide, protein or high mol. wt. cpd. as stabiliser

Patent Assignee: CHUGAI SEIYAKU KK (CHUS ); SHONAN KIKO KK (SHON-N);

CHUGAI PHARM CO LTD (CHUS )

Inventor: MACHIDA M M; MACHIDA M

Number of Countries: 023 Number of Patents: 036

Patent Family:

Patent No		Kind	Date		olicat No	Kind	Date	Week	
DE	3723781	A	19880121	DE	3723781	A	19870717	198804	В
GB	2193631	A	19880217	GB	8716904	. <b>A</b>	19870717	198807	
FR	2601591	Α	19880122		8710156	A	19870717	198811	
NL	8701640	A	19880216	NL	871640	Α	19870713	198811	
ΑU	8775665	A	19880121				•	198812	
NO	8702966	A.	19880215					198812	
SE	8702907	Α	19880119					198812	
DK	8703683	A	19880119					198815	
ZA	8705268	Α	19880127	ZΑ	875268	A	19870717	198818	
HU	44941	T	19880530				•	198825	
JP	63146826	Α	19880618	JP	87178031	А	19870716	198830	
JP	63146827	A	19880618	JΡ	87178032	A	19870716	198830	
JP	63146828	Α	19880618	JP	87178034	A	19870716	198830	
JP	63152326	A	19880624	JP	87178033	A	19870716	198831	
PT	85343	Α	19880729					198835	
ΒE	1000253	Α	19880927	BE	88787	А	19880927	198840	
CN	8704963	A	19880224					198915	
СН	671157	Α	19890815					198937	
	2010226	Α	19891101	ES	872106	Α	19870717	199004	
GB	2193631	В	19901121					199047	
	1218927	В	19900424					199211	
	1297007	С	19920310					199216	
	171828	В	19930201		872966	А	19870716	199310	
	83220	Α.	19930131		83220	А	19870717	199311	
	9304597	В1	19930601		877804	Α	19870718	199423	
	2025120	C1	19941230		4203033	. A	19870717	199531	
SE	503312	C2	19960513		872907	А	19870717	199625	
	8701775	Α	19960815		871775	A	19870714	199637	
	171308	В	19960902		873683	A	19870715	199641	
JP	2577742	B2	19970205		87178031	А	19870716	199710	
JΡ	2577743	B2	19970205		87178032	A	19870716	199710	
ΑT	402259	В	19970215		871775	А	19870714	199713	
JP	2629000	B2	19970709		87178033	A	19870716	199732	
NL	192917	В	19980105		87,1640	А	19870713	199807	
PH	28830	Α	19950314		35555	, A	19870717	199844	
DE	3723781	C2	19990902	DE	3723781	A	19870717	199939	

Priority Applications (No Type Date): JP 86169489 A 19860718; JP 86169486 A 19860718; JP 86169487 A 19860718; JP 86169488 A 19860718; JP 87178031 A 19870716; JP 87178032 A 19870716; JP 87178033 A 19870716
Patent Details:

```
Patent No
           Kind Lan Pg
                         Main IPC
                                      Filing Notes
DE 3723781
              Α
NO.171828
                                      Previous Publ. patent NO 8702966
              В
                       A61K-037/02
RU 2025120
              C1
                    10 A61K-009/14
DK 171308
              В
                       A61K-038/18
                                      Previous Publ. patent DK 8703683
JP 2577742
              B2
                     6 A61K-038/00
                                      Previous Publ. patent JP 63146826
JP 2577743
                                      Previous Publ. patent JP 63146827
              B2
                     6 A61K-038/00
AT 402259
                                      Previous Publ. patent AT 8701775
              В
                       A61K-038/19
JP 2629000
              В2
                     5 A61K-038/00
                                      Previous Publ. patent JP 63152326
NL 192917
              В
                    11 A61K-047/00
                       A61K-037/02
IL 83220
              Α
KR 9304597
              В1
                       A61K-037/02
              C2
SE 503312
                       A61K-038/19
AT 8701775
              Α
                       A61K-038/19
PH 28830
              Α
                       A61K-031/715
DE 3723781
              C2
                       A61K-038/16
```

Abstract (Basic): DE 3723781 A

A pharmaceutical contains stabilised G-CSF (granulocytes colony stimulating factor) as active ingredient and at least one surfactant, saccharide, protein or a high mol. wt. cpd. Pref. the amt. of surfactant or saccharide is 1-10000 pts. wt. Pref. pt. wt. G-CSF. Pref. the surfactant is non-ionic (esp. a sorbitan ester glycerine ester, poly-glycerine ester, polyoxyethylene sorbital ester, polyoxyethylene-glycerine ester or polyethylene glycol ester of an aliphatic acid, polyoxyethylene polyoxypropylene alkyl ether, a hardened polyoxyethylated castor oil, a polyoxyethylated bees wax deriv. a polyoxyethylene lanoline deriv. or an aliphatic polyoxyethylene acid aride), anionic (esp. an alkylsulphate or alkylsulpho succinyl ester salt) or natural (esp. lecithin, sphingophospholipid or an ester of an aliphatic acid with sucrose.

USE/ADVANTAGE - G-CSF can be used to treat various infectious diseases, but is unstable and highly sensitive to changes in the environment e.g. temp., humidity, oxygen or UV light. The invention stabilises the G-CSF and protects it completely against loss of activity.

Title Terms: PHARMACEUTICAL; STABILISED; GRANULOCYTE; COLONY; STIMULATING; FACTOR; CONTAIN; SURFACTANT; SACCHARIDE; PROTEIN; HIGH; MOLECULAR; WEIGHT ; COMPOUND; STABILISED

Derwent Class: A96; B04

International Patent Class (Main): A61K-009/14; A61K-031/715; A61K-037/02; A61K-038/00; A61K-038/16; A61K-038/18; A61K-038/19; A61K-047/00

International Patent Class (Additional): A61K-009/08; A61K-031/70;

A61K-035/00; A61K-037/00; A61K-037/04; A61K-037/12; A61K-037/43;

A61K-038/17; A61K-045/05; A61K-047/10; A61K-047/14; A61K-047/20;

A61K-047/24; A61K-047/26; A61K-047/32; A61K-047/34; A61K-047/36;

A61K-047/42; C12N-000/00

File Segment: CPI